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Abstract  
Background: Influenza is a disease affecting the human respiratory system. A common 
problem is to confuse colds with influenza, which results in problems with vaccination 
and complications related to influenza. Particular attention should be paid to the treatment 
of influenza, as it is a serious health risk if not treated in the elderly. Research conducted 
by scientists from Taiwan shows that currently the best way to protect against influenza is 
preventive vaccination. In addition to vaccination, antiviral drugs (Oseltamivir, 
Zanamivir, Amantadine, Rimantadine), antipyretics (aspirin, paracetamol) are used. 
Attention is paid to natural methods (ginseng extract, root lichen extract) and supplements 
(vitamin C, zinc). 
 
Material and Methods: This article is based on a review of the current state of 
knowledge on influenza in the elderly. The most up-to-date literature with EBSCO, 
Google Scholar and PubMed has been reviewed. Key words such as influenza, influenza 
complications, vaccinations, influenza treatment. 
 
304 
Results: In the context of the above topics, particular attention is paid to the elderly, in 
whom a low level of immunity predisposes to getting sick. An increase in the incidence of 
disease causes an increase in the mortality of older people. Complications following the 
occurrence of influenza are closely related to the type of virus, where the influenza A 
virus classified as the heaviest in the course. It has been proven that the bird influenza 
virus is also a threat to humans. The classic symptoms of influenza are cough, fever, while 
complications associated with untreated influenza are primarily myocarditis or 
pneumonia. 
 
Conclusion: Due to the decline in immunity, older people are particularly at risk of 
influenza virus. Scientists have demonstrated the high effectiveness of protective 
vaccination, but one should remember to repeat them every year. Vaccinations in the 
elderly have reduced effectiveness, which is why antiviral therapies, natural methods and 
supplements are used. In the rational treatment of influenza, it is noted that natural 
methods and supplements are an addition to classic antiviral therapy. 
  
Key words: influenza in the elderly, complications from influenza, vaccinations, 
influenza treatment  
 
Introduction  
Influenza is an acute illness caused by viruses (influenza virus) that attack the 
respiratory system [1]. Older people are particularly vulnerable to infections due to decreasing 
resistance with age. The incidence of influenza may be epidemic or seasonal [2]. 
 
Epidemiology in seniors is difficult to determine due to seasonal flu. Depending on the 
season, the incidence changes. Influenza viruses evolve all the time, obtaining immunity to 
the host's immune system [3]. They can act directly by destroying infected cells, damaging the 
respiratory epithelium or indirectly causing a number of symptoms. 
 
The most characteristic symptoms of influenza include high fever, sore throat and 
muscle pain. Other common symptoms include joint pain and lack of appetite. Older people 
are often accompanied by pneumonia during influenza. According to the World Health 
Organization, every year 0.5-1 million people die from complications of influenza [4]. Among 
the elderly, complications of influenza and pneumonia are the fifth most common cause of 
mortality [5]. 
 
The basic preventive measures against influenza include preventive vaccination. 
Neuraminidase inhibitors are very helpful in the treatment of influenza infection. It is worth 
remembering that over-the-counter drugs are used only to reduce the symptoms of influenza, 
they do not prevent its occurrence [6]. 
 
Why are aging people more vulnerable  to influenza? - epidemiology and mortality.  
Influenza is a  threat for elderly people due to physiological decreasing efficiency of 
immune system, which leaves the organism vulnerable to the development of infection. 
Unfortunately, in this age group, the flu is the leading cause of death with infectious aetiology 
[7]. Sadly, there still is  the limited availability to determine the exact number of patients.  
 
In fact, the incidence of influenza in elderly people from Eastern Europe is significant. 
In older adults the increasing of hospitalization and deaths were observed. [8]  According to 
the global mortality estimates from 1999- 2015, 39% of people between 65-74 age and  32% 
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older than 75 age, died due to influenza – associated causes. In 75 age and older group, the 
one of highest mortality rates were estimated.  The season’s mortality is correlated with the 
type of virus and its circulation, climate, temperature and country.  Moreover, to be sure, that 
influenza occurs and eventually it is the cause of death, the virologic tests should be 
performed. It is not often practise [9]. 
 
In 10 countries of Europe, in season 2016/17, 3959 number of cases were confirmed 
as an influenza, but 2827 had available age information. In group of 60-69 age, there was 
approximately 600 number of cases, similarly in group 80 and older. Around 800 patient 
between 70-79 was reported as having a influenza virus. In season 2016/17 the type A 
predominated. 
 
 In season 2017/18 7789 number of cases were confirmed  as an influenza. In 4754 
patient the information of age was available. Approximately 1200 patients were between 60-
69 age, thereabout 1000 were between 70- 79 age. In age 80 and older, the number of 
confirmed cases was nearly 600.  More cases was reported as a type B [10]. 
  
Cold or influenza? - characteristics.  
A usual cold is a mild and self-limiting viral disease that can be caused by more than 
200 types of viruses,  of which the most common  are rhinovirus and coronavirus. Often, the 
duration of a cold does not exceed 1-2 weeks, and most patients feel better after the first 
week. In people with chronic diseases, the common cold may be life-threatening, but most 
patients undergo severe but clinically harmless cold symptoms. Many of these people, in 
particular children and the elderly, enjoy symptomatic treatment as well as antibiotic therapy, 
despite the absence of a bacterial pathogen. A very small proportion of cold cases do not 
resolve spontaneously. Complications are very rare and affect infants, the elderly, people with 
immunodeficiency and chronically ill [11,12]. 
 
Some aspects of the body's inflammatory response may protect against viral infections, 
as the number of cytokines and  lung function increases during the infection. This suggests 
that we should not always try to reduce inflammation during viral upper respiratory tract 
infections [11]. 
 
Thanks to new knowledge about cytokines and their impact on our body, we 
understand some of the symptoms that occur in flu or cold, for example: fever, headache and 
muscle pain, runny nose, sneezing, chill or malaise [13]. These symptoms are much milder 
than those in the flu. 
 
Influenza is a viral disease that, thanks to the continuous mutations that the influenza 
virus undergoes, causes annual epidemics, as well as occasional pandemics that occur at 
irregular intervals. For this reason, the flu is a disease that can not be eradicated. Influenza can 
lead to serious complications and even deaths, not counting economic losses. We distinguish 
two important types of influenza virus, which are the main cause of infection infecting 
humans - type A and type B. Frequent mutations of the influenza virus occur mainly in virus 
surface glycoproteins, but also can occur in each of the 8 gene segments in both type A and B 
virus. Molecular changes in the viral RNA segments arise through various mechanisms: 1) 
genetic reassortment (antigenic shift), 2) point mutations (antigen drift), 3) defective-
interfering molecules, 4) RNA recombination. Thanks to these mechanisms, there is a 
constant evolution of influenza viruses. The influenza virus has a segmented genome, which 
also contributes to high variability of the genotype and phenotype [14]. 
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A cold is quite often confused with influenza. This leads to the reporting of cold cases 
as a flu, and the ill person who has been vaccinated has unconsciously acquired a negative 
attitude to influenza vaccination. The result of a disrespectful approach to these vaccinations 
is the increased risk of multiorgan complications of influenza. 
 
Typically, post-influenza complications result from the fact that the influenza virus, 
entering the respiratory system, damages the epithelium, thus opening the way for bacteria 
and viruses. The most common complication of flu is pneumonia and it is in the sixth place of 
the cause of death, and in the 5th position in the case of the elderly. Not only the 
complications of influenza are the direct cause of increased mortality during the flu epidemic. 
Exacerbation of already existing diseases of the respiratory system, circulatory system and 
other chronic diseases in people with flu contributes to the increase in mortality [15]. 
  
Influenza treatment and its efficiency.  
        Untreated flu, especially in elderly people can lead to many complications such as 
difficult to treat upper respiratory tract infection, pneumonia or myocarditis. Currently, 
vaccination is the most important way to protect against flu. Unfortunately, in addition to the 
fact that vaccinations need to be repeated each year, their effectiveness is also lower in the 
elderly. For the above reasons, in addition to, natural methods, supplements and symptomatic 
therapy, it is very important to use antiviral drugs such as neuraminidase inhibitor – 
Oseltamiwir and Zanamiwir or M2 protein inhibitors - Amantadine and Rimantadine. 
 
        Oseltamivir and Zanamivir are newer generation antiviral drugs. These are 
neuraminidase inhibitor that inhibit the replication of both influenza A and B viruses 
[16].  Oseltamivir commercial product is Tamiflu. It was the main drug used during the 2009 
influenza epidemic. Zanamivir is taken by inhalation. Its commercial product is Relenza. 
Zanamivir has a very low tendency to select for resistance, which is why it is a frequently 
used medicine [17]. Both drugs show the highest efficacy when therapies begin within 24-48 
hours of the onset of fever. They accelerate the time to return to full activity, reduce the 
severity of symptoms and the risk of serious complications. These drugs are well tolerated by 
elderly patients and those with other associated diseases. 
 
       Amantadine and Rimantadine are the first medicines that have been registered as 
preparations for the treatment of influenza. They are inhibitors of the M2 protein, which 
occurs only in the influenza A virus. Similarly to the neuraminidase inhibitors, their activity is 
also the highest for the first 48 hours after the onset of symptoms [18].  When using these 
drugs, gastrointestinal symptoms are often observed. Rimantidine may also cause central 
nervous system disorders [19]. Therefore, special care should be taken when using these 
medications, especially in elderly patients. 
 
        John H Beigel, Yajing Bao, Joy Beeler published an article about the study that 
examined the efficacy of combination therapy with oseltamivir, amantidine and 
ribavirin   compared to oseltamivir monotherapy for the treatment of influenza. The clinical 
effects of monotherapy and combination therapy were very similar. During the study one of 
the patient died from cardiovascular causes. This was not related to participation in the 
experiment [20]. However, it should be remembered that the elderly often take many 
medications that can interact with each other. Therefore, if monotherapy gives similar clinical 
effects in the treatment of influenza, it should be more preferred than the treatment of several 
antiviral drugs at the same time.  
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       Another group of drugs used in the treatment of influenza are antipyretic drugs such as 
aspirin and paracetamol. These are medicines that can reduce the severity of some flu 
symptoms. However, they can prolong the duration of the disease, because fever is one of the 
most important defense mechanisms of the body [21]. Additionally, Aspirin as a non-steroidal 
anti-inflammatory drug may increase the risk of gastrointestinal bleeding, which may be 
particularly vulnerable to elderly patients [22]. 
 
       Extremely important in the treatment of influenza are also supplements and natural 
methods. Some of them were already known in antiquity. These include medicinal 
preparations of plant origin such as ginseng extract or root lichen extract, which can be used 
in both prophylaxis and treatment. It is also worth using supplements like vitamin C and zinc, 
which can reduce the duration of colds and flu. However, it should be remembered that 
natural methods and supplements should be only an addition to antiviral therapy [23]. 
 
Complications of influenza - why is it so dangerous?  
        Influenza viruses can cause symptoms of particularly high severity. They are most 
often possible to be self-cured, but unfortunately in many cases, complications can also lead 
to death. Children, elderly people, as well as people suffering from chronic respiratory and 
circulatory system disorders and others who have an adverse effect on immunity are 
particularly vulnerable to this disease [24,25]. 
 
     Existing types of influenza viruses determine the occurrence of various complications, 
of which the A virus is responsible for the most severe in the course - is the cause of 
epidemics and pandemics, including even entire continents [24,25,27]. According to statistics, 
as a result of a pandemic in 1918, there were 20 million deaths [24,26]. Infection with 
influenza virus also causes degeneration of bronchial epithelium. In person’s deprived of 
diseases of individual body systems, it is regenerated and  functions are restored. This 
process, however, is undefined in time, and the long-lasting one causes increased cough and 
excessive reactivity of the bronchi. People with respiratory problems, such as asthma, have 
worsening symptoms and symptoms of influenza [24]. 
 
      As the research shows, the types of virus A and B also affect the efficiency of human 
cognitive functions. They cause increased drowsiness, social isolation and emotional sphere 
disorders. It is supposed that this is due to the increased immune response from the nervous 
system, which in turn leads to weakening of cognitive processes. According to another 
hypothesis - infection of the nervous system caused by the influenza virus carries with it the 
multiplication of it in the CNS, which in turn leads to the leveling of nerve cells responsible 
for brain efficiency. For this reason, the influenza virus may show some mental illnesses or 
cause neurodegeneration [27]. 
 
      Since 1997, the influenza virus (HPAI) causing the so-called bird flu has become 
pathogenic to humans. It caused havoc on farms, also reaching the human community. 
According to statistics conducted by WHO over the period 1997-2014, 394 people died due to 
avian influenza [26]. 
 
      The most common consequence of influenza is pneumonia with a viral nature, in 
which the symptoms are observed, and sometimes hemoptysis. Other symptoms are dyspnoea 
and cyanosis, as well as changes in the bronchial tree causing respiratory failure. This applies 
mainly to people already burdened with cardiovascular and respiratory diseases who have 
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reduced immunity. There is a risk of developing this disease also in young people. Pneumonia 
can also occur in a bacterial form when the viral form has not developed. Symptoms that 
accompany a sick person include fever, cough containing purulent secretion and disturbances 
in the functioning of defense mechanisms. Another complication is bronchiolitis obliterans, 
the rarest form of the consequences of influenza, but not impossible. It involves inflammation 
of the walls of the bronchi and bronchioles and tissues that surround them. It is a form that 
can develop mainly in young children [24]. 
 
       The consequences of influenza also include the cardiovascular system, leading to the 
onset of heart attacks, strokes and strokes belonging to the group of cerebrovascular diseases. 
They can also cause a disturbance in the functioning of the mitral valve, which prevents blood 
from going back from the left atrium to the left ventricle. Such disorders cause an increase in 
pressure in the left atrium, which determines the increase of its capacity, and thus the 
irregularity in its contraction [24, 27]. 
 
Vaccination as the most effective way to avoid influenza. 
One of the proofs that vaccines are the most effective way to avoid influenza in 
various clinical conditions is the study of scientists in Taiwan. They noticed the connection 
between  protective effect of influenza vaccination on outcomes in geriatric stroke patients. 
As it turned out stroke patients with influenza vaccination (IV) showed better outcome than 
non-vaccinated patients. They also showed fewer complications and lower mortality 
compared with non-IV patients. These findings suggest the urgent need to promote IV for 
this susceptible population of stroke patients [28]. 
 
Vaccines are also an invaluable weapon in the fight against weakness of immune 
system after an operation of the body. Vaccinated elderly patients who underwent surgery 
had a lower risk of pneumonia and in-hospital mortality.  Their results were compared with 
non-vaccinated patients who had undergone similar serious surgery [29]. As older patients 
are more often exposed to various types of surgical procedures, vaccination of geriatric 
patients is particularly important as they are also often exposed to more serious 
complications and worse final effects associated with them.  
 
In other studies, we can observe how enormous benefits are brought not only by the 
vaccination of a particularly vulnerable person, but also people in their environment. A 
study in the US investigated the effect of vaccinating hospital workers on patients' influenza 
incidence. The results shows that increased rates of vaccination by HCW (health care 
workers) were associated with a reduction in the proportion of hospital flu infections in 
immunocompromised patients [30]. 
 
In another of the published studies, this time carried out in Japan, we can read that 
influenza vaccine has shown good preventive action against hospitalization associated with 
influenza in the elderly [31]. This is just an example of one of the many studies conducted 
on this subject, which proves that vaccines are the best means to reduce the incidence of flu 
and hospitalization related to it worldwide. 
 
In addition, researchers in the US have noticed that in addition to anti-flu, this vaccine 
may have other benefits. As it turns out, this vaccine may have immune-modifying effects. 
This effect may be associated with an immune response to certain vaccine antigens. This is 
just the beginning of research on this issue, but it certainly will not end in this one study.  
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After numerous tests, it may turn out in the future that the vaccine against influenza is not 
enough that it is the best way to prevent this disease, it also has other, additional properties 




The aim of this article is to show how serious is the problem of influenza among older 
people, as well as the consequences resulting from complications and treatment methods 
and prophylaxis. 
Older people, according to statistics, belong to the group with a particularly high risk 
of developing influenza [10]. This is due to a number of reasons among which one should 
mention the already not-so-efficient immune system, as well as numerous comorbidities 
that burden the body. More importantly, the history of influenza infection in the elderly is 
a risk factor for these complications in the form of pneumonia, the leading cause of death 
[33]. Unfortunately, in the case of virostatic drugs that inhibit the influenza virus, such as 
amantadine, therapeutic efficacy can only be expected if treatment is undertaken within 
the first 48 hours after the onset of symptoms, and the time of treatment is often delayed 
due to difficulty in varying the flu from the common cold. However, symptomatic 
treatment in the case of older people may prove to be additional or insufficient. The 
inconvenience of treatment, as well as the growing population of older people, 
necessitates the development of strategies allowing effective prevention. The most 
effective are the vaccines. According to the recommendations of the Advisory Committee 
on Immunization Practices (ACIP), vaccination against influenza should apply to all 
people over 6 months of age in the absence of contraindications [36]. At the same time, 
according to the WHO, vaccinations are particularly recommended, among others, for 
people aged 65 and older. As part of preventive programs, they are available free of 
charge in countries such as Canada, Australia or Great Britain [35]. 
 
In addition, it should be noted that vaccination carries a small risk of side effects. A 
meta-analysis of 29 studies on 3 classes of adjuvanted vaccine: AS01 / AS02, AS03 and 
MF59 showed no significant adverse effects  compared to control vaccines. It should be 
noted, however, that adjuvanted vaccines are more reactive and are associated with a 
higher incidence of irritability, drowsiness or loss of appetite. Similarly, in the case of 
high-dose vaccines, the risk of adverse reactions is comparable to the risk associated with 
the use of standard vaccines in older people - there is no increased risk of side effects [35]. 
 
Although influenza vaccination is the most effective form of prophylaxis, one should 
take into account their reduced effectiveness in the elderly population. This is due to the 
weakened immune response, which is directly submitted to, lower than in younger people, 
effectiveness of vaccination. The disproportion between the population of older and 
younger people is visible in every type of influenza virus. The effectiveness of vaccination 
for people at working age is estimated at 51%, with an efficacy of 37% for older people 
[37]. In order to increase the effectiveness of vaccination among the elderly, it seems 
necessary to optimize the antigenic fit between the vaccine and the dominant strain of 
influenza in the environment [35]. 
 
Attention should also be paid to medical personnel dealing with elderly people. These 
people should  undergo yearly vaccinations against influenza as well, because during flu 
seasons their direct contact with patients carries a high risk of transferring the virus to 




Influenza is a common viral disease which can have very dangerous consequences, 
including death. It causes neurological, respiratory, gastrointestinal and musculoskeletal 
symptoms. It has seasonal activity and may lead to epidemic.  
 
Elderly people should be really careful as they are more vulnerable to the disease. The 
immune system is less effective with age and is often  not able to manage the fight with 
attacking viruses. In one season in Europe there are thousands  of influenza cases among 
elderly.  It is one of the most common reason of death in this group, especially in patients 
with chronic diseases of cardiovascular or respiratory system. 
 
Many people do not see the significant difference between cold and influenza. It is 
important to distinct them.  Cold is usually caused by rhinoviruses or coronaviruses and 
lasts about a week. Its symptoms like fever or muscle pain are milder than flu, there is also 
a runny nose and cough. Serious complications are rare, usually in patients with 
immunodeficiency. Influenza is caused by virus type A and B, but A is more 
dangerous.  Viruses have an ability to mutate its glycoproteins and RNA thanks to various 
mechanisms and this is why they are so difficult to eradicate. Influenza has more negative 
effect on organism than cold and is harder to treat. 
 
Influenza treatment involves antiviral drugs – neuraminidase inhibitors such as 
Oseltamiwir and Zanamiwir.  They are effective and safe. There are also M2 inhibitors – 
Amantadine and Rimantadine but they are used only against type A virus and may cause 
side effects affecting central nervous system. Monotherapy appears to be better than 
combination therapy of these drugs.  Aspirin and paracetamol are also used to reduce 
uncomfortable symptoms, they may weaken natural organism defense though.  Elderly 
often use natural methods and supplements to strengthen their immune system, but their 
efficiency is controversial. 
 
Special attention should be paid to complications caused by influenza as they may be a 
huge threat.  Virus A is the most problematic and may lead to pandemic and millions of 
deaths.  Asthmatic patients are more vulnerable to respiratory consequences such as 
bronchitis or pneumonia.  The disease can affect the nervous system causing degeneration 
of cells.  Elderly with chronic heart disease should take care of themselves thoroughly  
because their condition might worsen. 
 
It is essential to tell the patients about the importance of influenza vaccination every 
year. Studies showed that vaccinated stroke patients may avoid serious complications of 
influenza. Also those non-vaccinated  who were after surgery had higher chance of 
pneumonia than those vaccinated.  It is known that vaccine has a great effect on immune 
system and may reduce hospitalization and mortality rate. 
 
Influenza is underestimated but dangerous disease that may lead to life-threatening 
situations, especially in geriatric patients.  The virus is very insidious  because of  its 
frequent mutations.  Therefore, it should be examined all the time and  various new ways 
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